From molecule
to patient.

Follow a therapy through every stage — from the first spark of discovery to the person it heals — carried the whole way by a single Hakase engine.

Find the molecule worth pursuing.

Screen the ecosystem and the chemistry — targets, patents, compounds binding — to surface the candidate long before anyone else can see it.

Run the experiment before you run it.

A four-layer in-silico cascade predicts what the lab will measure — GO / Watch / No-Go — so real budget only touches the candidates that clear every gate.

Into the clinic, in real time.

Phase I through III — trial intelligence, plus the EDC, ePRO and CDISC operations that actually run the study, fused with live real-world data.

A filing that stands up. A therapy that ships.

Regulatory authoring and submission, built right the first time — from dossier to approval to a finished product on the shelf.

The point of all of it.

Real-world evidence from the bedside flows back upstream — sharpening the next molecule, the next trial, the next label. And a person gets their life back.